Zobrazeno 1 - 10
of 18
pro vyhledávání: '"Ornella Cantale"'
Autor:
Alessio Rizzo, Ornella Cantale, Andrea Mogavero, Lucia Garetto, Manuela Racca, Tiziana Venesio, Shobana Anpalakhan, Silvia Novello, Vanesa Gregorc, Giuseppe Luigi Banna
Publikováno v:
Thoracic Cancer, Vol 14, Iss 24, Pp 2473-2483 (2023)
Abstract Background Inflammation in non‐small cell lung cancer (NSCLC) may impair the response to immune checkpoint inhibitors (ICIs) and can be indicated by peripheral blood inflammatory indexes. 2‐deoxy‐2‐[18F]fluoro‐D‐glucose positron
Externí odkaz:
https://doaj.org/article/6ea1188252e842478259d526a9596ccf
Autor:
Ivana Puliafito, Federico Chillari, Alessandro Russo, Ornella Cantale, Dorotea Sciacca, Luigi Castorina, Cristina Colarossi, Tindara Franchina, Maria Paola Vitale, Giuseppina Rosaria Rita Ricciardi, Vincenzo Adamo, Francesca Esposito, Dario Giuffrida
Publikováno v:
Frontiers in Endocrinology, Vol 14 (2023)
BackgroundLung neuroendocrine neoplasms (NENs) are rare malignancies developed from bronchial mucosa. Because of its rarity and complex histopathology, there is limited data on the role of chemotherapy in this subset of tumors. Few studies regarding
Externí odkaz:
https://doaj.org/article/5b9b68db3bbc4daaaa657e8bcd742e49
Autor:
Ambrogio Gagliano, Angela Prestifilippo, Ornella Cantale, Gianluca Ferini, Giacomo Fisichella, Paolo Fontana, Dorotea Sciacca, Dario Giuffrida
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
Targeting cell cycle has become the gold standard for metastatic breast cancer (MBC), being cyclin-dependent kinase inhibitors (CDKIs) cornerstones of its treatment, alongside radiotherapy (RT). To date, no definite evidence regarding safety and effi
Externí odkaz:
https://doaj.org/article/2009b59c00f04daf976b87057fe6d230
Autor:
Giuseppe Luigi Banna, Ornella Cantale, Melissa Bersanelli, Marzia Del Re, Alex Friedlaender, Alessio Cortellini, Alfredo Addeo
Publikováno v:
Oncology Reviews, Vol 14, Iss 2 (2020)
Anti-PD1 and anti-PD-L1 agents may have intrinsic and clinically relevant differences in the treatment of non-small cell lung cancer (NSCLC) patients. By reviewing currently available indirect evidence on these agents for NSCLC treatment, highlightin
Externí odkaz:
https://doaj.org/article/cd486df0b0a84451ac9baef45060b823
Autor:
Giuseppe Luigi Banna, Ornella Cantale, Maria Monica Haydock, Nicolò Matteo Luca Battisti, Kevin Bambury, Naja Musolino, Eoin O’Carroll, Giuseppe Maltese, Lucia Garetto, Alfredo Addeo, Fabio Gomes
Publikováno v:
Banna, G L, Cantale, O, Haydock, M M, Battisti, N M L, Bambury, K, Musolino, N, O’ Carroll, E, Maltese, G, Garetto, L, Addeo, A & Gomes, F 2022, ' International Survey on Frailty Assessment in Patients with Cancer ', ONCOLOGIST, vol. 27, no. 10, pp. e796-e803 . https://doi.org/10.1093/oncolo/oyac133
Background Frailty negatively affects the outcomes of patients with cancer, and its assessment might vary widely in the real world. The objective of this study was to explore awareness and use of frailty screening tools among the ONCOassist healthcar
Autor:
Giuseppe Luigi Banna, Alessio Cortellini, Alain Gelibter, Sunil Daryanani, Ornella Cantale, Dario Giuffrida, Alex Friedlaender, Salvatore Caponnetto, Fabio Gomes, Alfredo Addeo
Publikováno v:
Journal of Molecular Pathology. 2:1-10
Patients with non-small-cell lung cancer (NSCLC), harboring Epidermal Growth Factor Receptor (EGFR) mutations, are more susceptible to brain metastases (BM). Comparisons of the efficacy of different-generation EGFR-tyrosine kinase inhibitors (TKI) on
Autor:
Domenico Galetta, Alfredo Addeo, Pamela Pizzutillo, Marco Banini, Giuseppe Luigi Banna, Diego Signorelli, Ornella Cantale, Marina Chiara Garassino, Alex Friedlaender, Alessandro De Toma, Giulio Metro
Publikováno v:
Transl Lung Cancer Res
The identification of prognostic and predictive biomarkers for high-programmed cell death-ligand 1 (PD-L1) advanced non-small cell lung cancer (aNSCLC) treated with first-line pembrolizumab could support the decision-making about possible combination
Autor:
Raffaele Giusti, Giorgia Guaitoli, Mario Occhipinti, Diego Cortinovis, Ornella Cantale, Luca Cantini, Cinzia Baldessari, Alessio Cortellini, Francesco Grossi, Linda Pettoruti, Vincenzo Sforza, Giovanni Mansueto, Francesco Passiglia, Francesca Mazzoni, Lorenza Landi, Alain Gelibter, Melissa Bersanelli, Daniele Santini, Paolo Marchetti, Alessandro Morabito, Alessandro Leonetti, Marianna Tudini, Serena Ricciardi, Fabrizio Citarella, Ettore D'Argento, Francesca Rastelli, Matteo Santoni, Vincenzo Di Noia, Giampiero Porzio, Robert A. Belderbos, Claudia Proto, Simona Scodes, Marianna Macerelli, Marco Filetti, Joachim G.J.V. Aerts, Diego Signorelli, Luigi Della Gravara, Carlo Genova, Danilo Rocco, Lorenzo Antonuzzo, Alessandro Tuzi, Cristina Cecchi, Luca Sala, Corrado Ficorella, Marco De Filippis, Giuseppe Luigi Banna, Alessandro Inno, Mariangela Torniai, Pamela Pizzutilo, Emilio Bria, Maria Giovanna Dal Bello, Domenico Galetta, Federico Cappuzzo, Federica Bertolini, Rossana Berardi, Maria Rita Migliorino, Miriam Grazia Ferrara, Clelia Donisi, Rita Chiari, Alessandro De Toma, Olga Nigro, Michele Ghidini, Annamaria Catino, Alfredo Addeo, Federica Zoratto, Alessandro Follador, Pietro Di Marino, Alex Friedlaender, Marco Russano, Biagio Ricciuti, Katia Cannita
Publikováno v:
Clinical Lung Cancer, 21(6), 498-508.e2. Elsevier
The role of immune-related adverse events (irAEs), as a surrogate predictor of the efficacy of checkpoint inhibitors, has not yet been described in the setting of first-line, single-agent pembrolizumab for patients with metastatic non-small-cell lung
Autor:
Alex Friedlaender, Addeo Alfredo, Ornella Cantale, Shyamika Acharige, Giuseppe Luigi Banna, Harliana Mohd Yusof
Publikováno v:
Cancer investigation. 40(5)
The impact of systemic anticancer treatments on SARS-CoV-2-related mortality is still debatable.By a retrospective analysis of patients with non-small-cell lung cancer (NSCLC) treated with first-line Pembrolizumab or in combination with chemotherapy
Background: Patients with cancer are vulnerable to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), although the impact of solid cancer types and systemic anticancer treatments on its related mortality is still debatable.Methods: To weig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d533a7176860ebc02049ef9b1880705e
https://doi.org/10.21203/rs.3.rs-167896/v1
https://doi.org/10.21203/rs.3.rs-167896/v1